Twist Bioscience Corporation (NASDAQ:TWST) on Friday posted mixed fourth-quarter results, reporting a loss of 45 cents per share, slightly wider than the consensus estimate of a 43-cent loss.

Sales reached $99.01 million, up 17% year over year, beating the consensus of $97.32 million.

Adjusted EBITDA loss for the fourth quarter was $7.8 million compared to a loss of $17 million a year ago.

The company shipped products to approximately 3,800 customers in 2025, compared to approximately 3,550 a year ago. Twist shipped approximately 938,000 genes compared to approximately 772,000 genes a year ago.

Gross margin for the fourth quarter of fiscal 2025 increased to 51.3% compared to 45.1% a year ago.

Outlook

Twist Bioscience expects fiscal 2026 sales of $425 million-$435 million versus the consensus ...